Integrative Analysis of CRC Liver Metastasis

NCT ID: NCT02917707

Last Updated: 2016-09-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-01-31

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators will perform integrative analysis of CRC liver metastasis

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators will analyzed proteomes of paired normal colorectal tissues and colorectal cancer (CRC) with or without liver metastasis, sequenced transcriptomes, performed whole exome sequencing, and single nucleotide polymorphism (SNP) array profiling for triplets, each comprising normal colorectal tissue, primary colorectal carcinoma, and its synchronous matched liver metastasis, as well as analyzed genomics of CRC characterized previously by The Cancer Genome Atlas (TCGA) to conduct integrated proteogenomic analyses.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metastasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

normal colorectal tissues (PN)

normal colorectal tissues

normal colorectal tissues

Intervention Type OTHER

The investigators will extract total protein, DNA and RNA from these groups.

primary colorectal carcinoma tissues

primary colorectal carcinoma tissues

normal colorectal tissues

Intervention Type OTHER

The investigators will extract total protein, DNA and RNA from these groups.

liver metastasis tissues

liver metastasis tissues

normal colorectal tissues

Intervention Type OTHER

The investigators will extract total protein, DNA and RNA from these groups.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

normal colorectal tissues

The investigators will extract total protein, DNA and RNA from these groups.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

primary colorectal carcinoma tissues liver metastasis tissues

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≤ 75 years with histologically proven CRC
* No severe major organ dysfunction
* WHO performance status of 0 or 1
* No prior cancer chemotherapy

Exclusion Criteria

* Age ≥ 76
* Severe major organ dysfunction
* World Health Organization (WHO) performance status of \>1
* Prior cancer chemotherapy
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ganzhou City People's Hospital

OTHER

Sponsor Role collaborator

Da Fu

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Da Fu

Principal Investigator

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Da Fu, Ph.D.

Role: PRINCIPAL_INVESTIGATOR

the Shanghai Tenth People's Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ganzhou City People's Hospital

Ganzhou, Jiangxi, China

Site Status RECRUITING

Shanghai Tenth People's Hospital

Shanghai, Shanghai Municipality, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Da Fu, Ph.D.

Role: CONTACT

021-66301604

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Xiaoming Zhong, MD

Role: primary

00-86-797-8356156

Da Fu, Ph.D.

Role: primary

00-86-21-66301604

References

Explore related publications, articles, or registry entries linked to this study.

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015 Mar;65(2):87-108. doi: 10.3322/caac.21262. Epub 2015 Feb 4.

Reference Type RESULT
PMID: 25651787 (View on PubMed)

Ma YS, Huang T, Zhong XM, Zhang HW, Cong XL, Xu H, Lu GX, Yu F, Xue SB, Lv ZW, Fu D. Proteogenomic characterization and comprehensive integrative genomic analysis of human colorectal cancer liver metastasis. Mol Cancer. 2018 Sep 21;17(1):139. doi: 10.1186/s12943-018-0890-1.

Reference Type DERIVED
PMID: 30241526 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Y219J11311

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.